Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

By Grassadonia Antonino   Cioffi Pasquale   Simiele Felice   Iezzi Laura   Zilli Marinella   Natoli Clara  

Cancers, Vol. 5, Iss. 3, 2013-07 ,pp. : 919-942

MDPI

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors as Anticancer Drugs

By Eckschlager Tomas   Plch Johana   Stiborova Marie   Hrabeta Jan  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1414-1414

MDPI

Access to resources Recommend Favorite

Clinical Toxicities of Histone Deacetylase Inhibitors

By Subramanian Srividya   Bates Susan E.   Wright John J.   Espinoza-Delgado Igor   Piekarz Richard L.  

Pharmaceuticals, Vol. 3, Iss. 9, 2010-08 ,pp. : 2751-2767

MDPI

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

By Sleiman Sama F.   Berlin Jill   Basso Manuela   S.Karuppagounder Saravanan   Rohr Jürgen   Ratan Rajiv R.  

Pharmaceuticals, Vol. 4, Iss. 8, 2011-08 ,pp. : 1183-1195

MDPI

Access to resources Recommend Favorite

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

By Bishton Mark J.   Johnstone Ricky W.   Dickinson Michael   Harrison Simon   Prince H. Miles  

Pharmaceuticals, Vol. 3, Iss. 8, 2010-08 ,pp. : 2674-2688

MDPI

Access to resources Recommend Favorite